Implications of dynamic changes in miR-192 expression in ischemic acute kidney injury

Lulu Zhang1 · Yuan Xu1 · Song Xue2 · Xudong Wang2 · Huili Dai1 · Jiaqi Qian1 · Zhaohui Ni1 · Yucheng Yan1

Received: 29 July 2016 / Accepted: 9 December 2016 / Published online: 29 December 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose Ischemia–reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) with poor outcomes. While many important functions of microRNAs (miRNAs) have been identified in various diseases, few studies reported miRNAs in acute kidney IRI, especially the dynamic changes in their expression and their implications during disease progression.

Methods The expression of miR-192, a specific kidney-enriched miRNA, was assessed in both the plasma and kidney of IRI rats at different time points after kidney injury and compared to renal function and kidney histological changes. The results were validated in the plasma of the selected patients with AKI after cardiac surgery compared with those matched patients without AKI. The performance characteristics of miR-192 were summarized using area under the receiver operator characteristic (ROC) curves (AUC-ROC).

Results MiRNA profiling in plasma led to the identification of 42 differentially expressed miRNAs in the IRI group compared to the sham group. MiR-192 was kidney-enriched and chosen for further validation. Real-time PCR showed that miR-192 levels increased by fourfold in the plasma and decreased by about 40% in the kidney of IRI rats. Plasma miR-192 expression started increasing at 3 h and peaked at 12 h, while kidney miR-192 expression started decreasing at 6 h and remained at a low level for 7 days after reperfusion. Plasma miR-192 level in patients with AKI increased at the time of ICU admission, was stable for 2 h and decreased after 24 h. AUC-ROC was 0.673 (95% CI: 0.540–0.806, p = 0.014).

Conclusions Plasma miR-192 expression was induced in a time-dependent manner after IRI in rats and patients with AKI after cardiac surgery, comparably to the kidney injury development and recovery process, and may be useful for the detection of AKI.

Keywords miR-192 · Acute kidney injury · Cardiac surgery · microRNAs · Ischemia–reperfusion injury

Introduction

Acute kidney injury (AKI) is one of the most common complications in patients with prolonged hospital stays, increasing medical costs and poor outcomes [1]. Ischemia–reperfusion injury (IRI) is a major cause of AKI [1, 2], characterized by acute tubular necrosis [3]. However, the mechanisms underlying AKI development are unclear and diagnostic biomarkers have not been established, leading to the lack of specific treatment [4]. Recent studies identified proteins, including KIM-1 [5], NGAL [6] and IL-18 [7], as potential biomarkers in ischemic AKI. However, none of them has been validated or is routinely used in the clinic. Thus, the discovery and validation of additional reliable biomarkers are strongly needed to detect AKI [8].

MicroRNAs (miRNAs) are short, endogenous non-coding RNAs, 18–22 nt long, that regulate gene expression at the post-transcriptional level by targeting messenger RNAs and inhibiting translation [9]. MiRNAs have important functions in numerous biological processes [9].
Owing to their stability in the blood, urine and other body fluids, miRNAs are considered novel biomarkers in various diseases [10–12], including acute and chronic kidney diseases [13, 14]. Johan et al. determined that circulating miR-210 levels significantly increased in critically ill patients with AKI and was an independent and powerful predictor of 28-day survival [15]. A study on 120 adult patients undergoing cardiac surgery showed that miR-21 levels in the urine and plasma were upregulated in AKI patients and both were associated with AKI progression [16]. The areas under the curve (AUCs) for urine and plasma miR-21 associated with established AKI were 0.68 (95% CI: 0.59–0.78) and 0.80 (95% CI: 0.73–0.88), respectively [16]. However, no study evaluated variations of these miRNAs over time. Levels of specific miRNAs might vary during disease progression, and early detection of AKI is important for intervention. We postulated that dynamic changes in the levels of plasma miRNAs might be involved in the development of IRI and might be useful for the detection of AKI.

In the present study, we analyzed miR-192 expression levels in the plasma and kidney tissues from IRI rats after miRNA profiling and verified its changes in the plasma of patients after cardiac surgery at different time points to determine whether miR-192 can be used as a tool to detect IRI kidney injury.

Materials and methods

Ethics statement

All animal experiments were approved by the Animal Care and Use Committee of Ren Ji Hospital and carried out in accordance with the National Institutes of Health Guide for Use of Laboratory Animals. The human study was approved by the Ethical Committee of Ren Ji Hospital and in accordance with the principle of the Declaration of Helsinki. In addition, all patients signed informed written consent before cardiac surgery.

Animal model

Male Sprague–Dawley (SD) rats, weighing 150–200 g, were purchased from the SLAC Laboratory Animal Co. Ltd (Shanghai, China) and housed in animal cages with suitable conditions in the Animal Department of Renji Hospital. Rats were randomly grouped into the sham or IRI group. In miRNA PCR array and miR-192 validation study, nine rats in each group were euthanized after 24 h of reperfusion. In the time-course study, six rats from each group were euthanized 1, 3, 6, 12, 24 h, 3 or 7 days after surgery. The IRI procedures were performed as previously described [17]. Blood was collected from the abdominal aorta and placed into EDTA anti-coagulation tubes. Once harvested, one quarter of each kidney was placed into 10% formalin for histological examination, while the remaining was stored at \(-80\) °C after being snap-frozen in liquid nitrogen for other studies.

Patients

Ninety-three patients aged 40–80 years, undergoing open cardiac surgeries in the Cardiac Surgery Division of Ren Ji Hospital from January 2014 to October 2014, were enrolled. All the patients with pre-existing end-stage renal disease requiring renal replacement therapy (RRT), cancer, diabetes, lupus nephritis, infection diseases, previous cardiac interventional therapy or minimally invasive cardiac surgery were excluded. Among them, 35 (37.6%) patients developed AKI, including 26 (28.0%) of Stage 1, 5 (5.4%) of Stage 2 and 4 (4.3%) of Stage 3. Thirty-five patients who developed AKI during the follow-up and thirty-five controls who also underwent open cardiac surgery, but did not develop AKI were matched at a 1:1 ratio based on age, sex, comorbidities and type of surgery in the subsequent study. The AKI diagnosis was defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria with a post-operative increase in plasma creatinine \(\geq 50\%\) from baseline or \(\geq 0.3\) mg/dL [18]. Patients who presented hemolysis in the plasma samples at two or more time points were also excluded. Plasma samples were collected at different time points, including preoperation, 0, 2, 24 and 72 h after admission to the intensive care unit (ICU).

Total RNA extraction

Plasma was obtained within 1 h by two-step centrifugation at 3000g at 4 °C for 15 min, followed by that at 12,000g at 4 °C for 15 min. The kidney homogenates were obtained by adding 400 μL of lysis buffer. RNA extraction was performed with TaqMan™ mirVana™ PARIS kit (ThermoFisher, Waltham, MA, USA) according to the manufacturer’s instructions.

MiRNA PCR array assay

MiRNAs were assessed by rodent TaqMan low-density array (TLDA) assay (ThermoFisher) according to the manufacturer’s instructions. An equal amount of three randomly selected samples was used to generate the pooled sample. Six pooled samples were obtained, three from each group. RNA was extracted from the six pooled samples. Reverse transcription, preamplification and PCRs were performed following the manufacturers’ protocols.
Quantitative real-time PCR

Real-time PCR was performed to validate rat and human plasma miRNA using TaqMan® microRNA reverse transcription kit (ThermoFisher), TaqMan® Universal Master Mix II, no UNG (ThermoFisher) and TaqMan® microRNA assay (ThermoFisher) according to the manufacturer’s instructions. The $2^{-\Delta\Delta Ct}$ value was calculated. Cel-mir-39 was used as a spike-in control for plasma miRNA normalization, while U6 was used as the internal control for rat tissue miRNA normalization.

Biochemical tests

Plasma urea nitrogen (BUN) and creatinine were detected by enzymatic method, using an automatic biochemical analyzer.

Histological examination

Histological examination was performed as previously described [19]. Tubular damage was scored by calculating the percentage of tubules in the corticomedullary junction that displayed tubular epithelia cell degeneration, cell necrosis, loss of the brush border, formation of lumen casts and tubular dilatation, as follows: 0, none; 1, $\leq 10\%$; 2, 11–25%; 3, 26–45%; 4, 46–75%; and 5, $>75\%$. One blinded observer assessed the tubular damage. Ten high-power fields (magnification, $200\times$) were examined for each rat.

Statistical analysis

All statistical analyses were performed with SPSS 16.0 software (SPS, Chicago, IL, USA). Continuous data were presented as mean ± standard deviation and compared by using Student’s $t$ test. Non-continuous data were presented as median (interquartile) and compared using Mann–Whitney U test. To compare categorical variables, we performed the $\chi^2$ or Fisher’s exact test, as appropriate. Multiple comparisons of variables within and between two groups of patients were compared by two-way ANOVA followed by post hoc nonparametric statistics. The AUC was calculated from a standard receiver operating characteristic (ROC) curve of microRNA for predicting AKI. $p < 0.05$ was considered statistically significant.

Results

Bilateral kidney ischemia–reperfusion induced an increase in plasma BUN, creatinine and tubular damage in a rat model

To determine the miRNA expression profile related to tissue injury and repair processes following AKI, we used a well-established model of bilateral renal IRI. After 45 min of ischemia and 24-h reperfusion, plasma BUN and creatinine were significantly elevated in the IRI group. In the sham group, BUN and creatinine were 7.67 ± 1.73 mmol/L and 23.3 ± 7.02 μmol/L, respectively. In the IRI group, BUN and creatinine increased to 29.95 ± 15.31 mmol/L and 112.05 ± 75.22 μmol/L, respectively (Fig. 1a, b). The histological staining further supported kidney injury. Significant tubular injury was observed in IRI rats presenting extensive tubular necrosis, loss of the brush border, cast formation and tubular dilatation in the corticomedullary junction (Fig. 1c, d).

Global microRNA profiling of IRI rats

Forty-two miRNAs differentially expressed were identified by rat plasma global miRNA PCR array, among which 22 were aberrantly expressed with more than threefold change between groups (Fig. 2a). There were fifteen elevated miRNAs and seven downregulated miRNAs.

Validation of altered microRNAs in the plasma and kidney tissues of IRI rats

Among the identified miRNAs, miR-192 was preferentially expressed in the kidney and showed more than a threefold change. Therefore, we chose miR-192 for further validation. As shown in Fig. 2b, the level of miR-192 in the plasma of IRI rats increased by about fourfold compared to that of the sham group. We further confirmed the expression of miR-192 in kidney tissues. In IRI rats, miR-192 expression was decreased by about 40% in the whole kidney, about 60% in the medulla and about 40% in the cortex, compared to the sham group (Fig. 2c).

Dynamic changes of plasma and kidney miR‑192 expression in IRI rats

To investigate how early miR-192 was changed after renal IRI, we observed the dynamic expression of miR-192 in the plasma and kidney tissues of IRI rats. BUN was significantly increased at 6 h after reperfusion, peaked at 12 h and returned to normal levels at 7 day of IRI (Fig. 3a). Plasma creatinine was significantly increased at 3 h after reperfusion, continued to increase at 12 h, finally returned to baseline at 3 day after IRI (Fig. 3b). H&E staining confirmed kidney injury (Fig. 3c). Levels of plasma and kidney miR-192 were assayed at 1, 3, 6, 12, 24 h, 3 and 7 day after 45 min of ischemia. Plasma miR-192 expression was elevated at 3 h after reperfusion, peaked at 12 h and returned to baseline at 3 day after reperfusion (Fig. 3d). However, the time-course study showed significantly decreased levels of miR-192 in kidney tissues of IRI rats, with an initial
decrease at 6 h and a continuous low level until 7 day after reperfusion (Fig. 3e).

Circulating levels of miR-192 increased in patients after cardiac surgery

To investigate the relationship between miR-192 and AKI, we observed the dynamic changes of plasma miR-192 levels in 70 patients who underwent cardiac surgery, 35 patients with AKI and 35 patients without AKI. As shown in Fig. 4a and Table 1, plasma miR-192 levels increased rapidly at 0 h after admission to the ICU and were stable between 0 and 2 h after surgery in patients who developed AKI. MiR-192 level at 24 and 72 h was similar to that of preoperation. The expression pattern of miR-192 in the non-AKI group was similar to that of the patients with AKI, except that miR-192 levels decreased at 2 h, but was still higher than that before operation. MiR-192 levels at 2 h after ICU admission in the AKI group were significantly higher than those in the non-AKI group. ROC curve analysis showed that miR-192 could be used to diagnose AKI (Fig. 4b). The area under the ROC curve (AUC-ROC) was 0.673 (95% CI: 0.540–0.806, p = 0.014) for plasma miR-192 at 2 h after ICU admission, indicating that plasma miR-192 can be an early marker for the detection of established AKI. When the cutoff value was 1.445, the sensitivity and specificity were 66.7 and 62.9%, respectively.

Baseline characteristics of patients after cardiac surgery

Patient characteristics are shown in Table 2. Of the 70 patients studied, 43 were males and 35 developed AKI after surgery. The mean patients’ age was 64.31 ± 8.17 years, and the preoperative plasma creatinine was 74.97 ± 16.25 μmol/L. Other characteristics of patients with or without AKI are shown in Table 2. There was no significant difference in sex, age, plasma creatinine level and comorbidities, including chronic kidney disease (CKD), hypertension, anemia and use of contrast medium and angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker (ACEI/ARB). The intraoperative variables, including the proportion of surgery type, operation time and cardiopulmonary bypass (CPB), were also similar. Coronary artery bypass graft (CABG) surgeries included on-pump CABG and off-pump CABG. Five patients underwent off-pump CABG and 3 of them developed AKI. The postoperative variables, including hypotension, low blood volume symptom and congestive heart failure, were comparable between groups. Seven patients developed an
infection during the follow-up; one developed an upper respiratory tract infection, while the others developed lung infections. One patient needed RRT after surgery, and the incidence of RRT was not statistically significant. All the three patients who died were in the AKI group.

Dynamic changes of plasma creatinine in patients

As shown in Table 3, the levels of plasma creatinine remained stable after cardiac surgery in the 35 non-AKI patients, except for a small increase at 24 h after admission to the ICU (about 1.15-fold). In the 35 AKI patients, the level of plasma creatinine at 24 and 72 h increased 1.84-fold and 1.49-fold compared to the preoperation levels. Although similar to the preoperation levels, plasma creatinine at 0 and 2 h in AKI patients was a little higher than that in non-AKI patients. The level of creatinine at 24 h after ICU admission in AKI patients was significantly higher than that in non-AKI patients.

Discussion

In the present study, we screened miRNAs in the plasma of IRI rats and identified 42 miRNAs with altered expression, among which 15 miRNAs were upregulated. In the time-course study, miR-192 expression in the plasma and kidney tissues of IRI rats varied in a time-dependent manner. In
the clinical study, plasma miR-192 at 2 h after ICU admission presented a modest predictive value for the diagnosis of AKI.

Our study showed dynamic changes of miR-192 expression in the plasma and kidney tissues of IRI rats. These dynamics correlated with histological findings of kidney injury and with increases in concentrations of known markers of renal dysfunction (BUN and creatinine). Thus, miR-192 may reflect kidney IRI. A previous study indicated that plasma miR-192 was upregulated at 6 h after reperfusion in IRI rats [20]. Moreover, the expression pattern of plasma miR-192 was discordant with that of kidney miR-192. Similarly, in a mouse study, Bellinger et al. [21] determined that the expression of few miRNAs changed in a coordinated manner, while that of most miRNAs in an uncoordinated manner. Saikumar et al. [22] demonstrated that kidney miR-21 and miR-155 were upregulated after IRI, while blood miR-21 and miR-155 were downregulated. Mechanistic relationships between renal and circulating miRNAs are unclear, and whether the increased circulating miRNA levels are solely of renal origin remains unknown. Elevated levels of certain miRNAs in the plasma may be the result of renal cell death associated with leakage of cytoplasmic components or active secretion from the surviving cells, membrane microparticles, exosomes or in protein-bound forms [23]. In a study of atherosclerosis, the delivery of miR-126 by endothelial cell-derived apoptotic bodies was found to be able to induce CXCL-dependent vascular protection [24], indicating that upon injury, apoptosis was switched on and miRNAs could be secreted into extracellular space or circulation in apoptotic bodies. Whether it was the same case in our study needed further study. The whole body is also thought to respond to a renal IRI, and circulating miRNAs might have originated from elsewhere besides the kidney. Circulating miRNAs could play an important role in interorgan communication rather than being mere bystanders of tissue injury [25]. Recent study found microvesicles carrying specific microRNAs released from endothelial progenitor cells exert a protective effect in experimental acute renal IRI [26]. Additional studies are needed to identify specific organ and cell types producing miRNAs.
There were several noteworthy points in our clinical study. Firstly, the plasma level of miR-192 in non-AKI patients at the time of admission to ICU (0 h) was also significantly higher than the preoperation level. This may be associated with cardiopulmonary bypass and cardiac IRI. Although miR-192 level in the heart tissue is much lower than that in the kidney, investigators showed that hypoxia induced miR-192 expression and excretion in the sera of patients with post-acute myocardial infarction (AMI) [27]. Moreover, miR-192 expression pattern in humans and rats seems to be different. The level of plasma miR-192 in AKI patients was significantly higher than that of non-AKI patients at 2 h after ICU admission. However, rat plasma miR-192 began to increase at 3 h after reperfusion. The fact that patients stayed in the anesthesia resuscitate room between cardiac blood flow restoration and ICU admission for a 1- to 2-h period may explain this discrepancy. In addition, only one time point difference in the level of miR-192 was observed and the AUC was not very high. Small number of cases, mild clinical AKI and limited time points between 2 and 24 h after reperfusion may have reduced the diagnostic value of miR-192 in AKI. Future studies with large sample size and intensive time points are warranted. The last thing to be noted was that although the incidence of AKI in our clinical study was similar to other previous studies [28], the severity of AKI developed in this study was relatively mild. Only 4 out of 35 AKI patients were with AKI stage 3, and only one of them needed RRT. That might be due to some risk factors for AKI, such as diabetes, lupus nephritis, infection diseases and pre-existing cancer that were excluded in this study in case of all these confounding factors affected the analysis of miR-192 levels.

In this study, the molecular mechanisms underlying the deregulation of circulating and renal miRNAs could not be determined. Previous studies suggest that miR-192 was linked to both G1 and G2/M cell cycle arrest in other contexts [29, 30] and was frequently downregulated in colorectal cancer, renal childhood neoplasms and multiple myeloma [31–33]. Roy et al. [34] recently found that tumor necrosis factor alpha (TNF-\(\alpha\)) was an upstream regulator of miR-192 in acute liver injury and confirmed a protective effect of downregulation of miR-192 in hepatocytes through Zeb2. The exact pathophysiological effect of these changes needs to be further investigated.

The miRNA PCR array also showed that several miRNAs decreased after IRI, which have not yet investigated. The purpose of this study was to identify a miRNA with diagnostic implications for AKI after IRI. Owing to the low abundance of miRNAs in the blood, if miRNAs are further decreased under disease conditions, the level of these miRNAs may be beyond the range of detection of the existing techniques. The mechanism underlying the down-regulation of these miRNAs is still not clear and should be

### Table 1 Plasma miR-192 levels of patients at different time points

| Time  | Non-AKI  | AKI       | \(p\) value (AKI vs. non-AKI) |
|-------|----------|-----------|-------------------------------|
| Pre   | 0.79 (0.41, 1.16) | 1.12 (0.47, 2.42) | 0.092                         |
| 0 h   | 1.65 (0.97, 2.36)** | 1.93 (0.93, 3.24)** | 0.277                         |
| 2 h   | 1.21 (0.88, 1.77)** | 1.80 (0.94, 5.10)** | 0.014                         |
| 24 h  | 0.39 (0.28, 0.67)** | 0.47 (0.29, 1.83)** | 0.196                         |
| 72 h  | 0.52 (0.22, 0.98) | 0.68 (0.23, 1.73) | 0.165                         |

AKI acute kidney injury

\( * p < 0.05 \) versus non-AKI patients

\( ** p < 0.05, *** p < 0.01, **** p < 0.001 \) versus prelevels
investigated. In addition, we observed dynamic changes of plasma miR-192 levels in patients undergoing cardiac surgery and provided a time window for clinical testing.

In summary, this study showed dynamic changes of plasma and kidney miR-192 levels in AKI and plasma miR-192 might be a predictor for ischemic AKI. Larger cohort

Table 2  Patient characteristics

|                                | All (n = 70) | Non-AKI (n = 35) | AKI (n = 35) | p value (AKI vs. non-AKI) |
|--------------------------------|-------------|-----------------|-------------|-------------------------|
| Preoperative variables         |             |                 |             |                         |
| Male n (%)                     | 43 (61.4%)  | 21 (60.0%)      | 22 (62.9%)  | 0.806                   |
| Age (years)                    | 64.31 ± 8.17| 62.66 ± 7.07    | 65.97 ± 8.93| 0.090                   |
| Plasma creatinine (µmol/L)     | 74.97 ± 16.25| 72.62 ± 15.36  | 77.33 ± 16.98| 0.259                   |
| eGFR (ml/min/1.73 m²)          | 90.64 ± 18.32| 93.22 ± 16.71  | 88.06 ± 19.71| 0.242                   |
| Body mass index                | 22.88 ± 3.42| 22.81 ± 3.45    | 22.95 ± 3.43| 0.867                   |
| Chronic kidney disease n (%)   | 17 (48.5%)  | 8 (22.9%)       | 9 (25.7%)   | 0.780                   |
| Hypertension n (%)             | 29 (41.4%)  | 13 (37.1%)      | 16 (45.7%)  | 0.467                   |
| NYHA >II n (%)                 | 16 (22.9%)  | 7 (20.0%)       | 9 (25.7%)   | 0.428                   |
| Use of contrast medium n (%)   | 36 (51.4%)  | 18 (51.4%)      | 18 (51.4%)  | 1.000                   |
| Use of ACEI/ARB n (%)          | 27 (38.6%)  | 14 (40.0%)      | 13 (37.1%)  | 0.806                   |
| Intraoperative variables       |             |                 |             |                         |
| Type of surgery                |             |                 |             |                         |
| Valve n (%)                    | 31 (44.3%)  | 15 (42.9%)      | 16 (45.7%)  | 0.810                   |
| CABG n (%)                     | 24 (34.2%)  | 13 (37.2%)      | 11 (31.4%)  | 1.000                   |
| CABG + valve n (%)             | 9 (12.9%)   | 4 (11.4%)       | 5 (14.3%)   | 1.000                   |
| Other operations n (%)         | 6 (8.6%)    | 3 (8.6%)        | 3 (8.6%)    | 1.000                   |
| Operation time (h)             | 5.36 ± 1.39 | 5.35 ± 1.19     | 5.38 ± 1.59 | 0.932                   |
| CPB n (%)                      | 52 (74.3%)  | 25 (71.4%)      | 27 (77.14%) | 0.584                   |
| CPB time (hours)               | 1.87 ± 0.85 | 1.78 ± 0.69     | 1.95 ± 0.99 | 0.487                   |
| Postoperative variables        |             |                 |             |                         |
| Hypotension n (%)              | 8 (11.4%)   | 2 (5.7%)        | 6 (17.1%)   | 0.223                   |
| Low blood volume n (%)         | 9 (12.9%)   | 2 (5.7%)        | 1 (20.0%)   | 0.127                   |
| Congestive heart failure n (%) | 3 (4.3%)    | 1 (2.9%)        | 2 (5.7%)    | 0.958                   |
| Infection n (%)                | 7 (10.0%)   | 3 (8.6%)        | 4 (11.4%)   | 0.934                   |
| RRT n (%)                      | 1 (1.4%)    | 0 (0%)          | 1 (2.9%)    | 0.485                   |
| Mortality n (%)                | 3 (4.3%)    | 0 (0%)          | 3 (8.6%)    | 0.217                   |

Table 3  Plasma creatinine levels of patients at different time points

|                  | Non-AKI |            | AKI          |            |
|------------------|---------|------------|-------------|------------|
|                  | Plasma creatinine (µmol/L) | Fold change<sup>a</sup> | Plasma creatinine (µmol/L) | Fold change<sup>a</sup> |
| Pre              | 72.62 ± 15.36 | / | 77.33 ± 16.98 | / |
| 0 h             | 72.46 ± 23.54 | 1.00 | 100.09 ± 27.14<sup>***</sup> | 1.31 |
| 2 h             | 68.23 ± 21.26 | 0.93 | 96.40 ± 28.20<sup>***</sup> | 1.26 |
| 24 h            | 82.94 ± 18.40<sup>g</sup> | 1.15 | 141.40 ± 55.92<sup>***</sup><sup>g</sup> | 1.84 |
| 72 h            | 70.88 ± 18.39 | 0.91 | 117.54 ± 70.43<sup>**</sup><sup>g</sup> | 1.49 |

<sup>a</sup> Fold change, versus prelevels

AKI acute kidney injury, eGFR estimated glomerular filtration rate. NYHA New York Heart Association grade for heart failure. ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker, CABG coronary artery bypass graft, CPB cardiopulmonary bypass, RRT renal replacement therapy

* p < 0.05, ** p < 0.01, *** p < 0.001 versus non-AKI patients; *p < 0.01, **p < 0.001 versus prelevels
studies are needed to confirm these findings, and further studies are required to identify the underlying molecular pathophysiological mechanisms.

Acknowledgements This study was sponsored by the National Natural Science Foundation of China (Nos. 81170687 and 81470918) and Shanghai Science and Technology Committee (No. 134119a2300).

Compliance with ethical standards

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Horino T, Terada Y (2014) Acute kidney injury: progress in diagnosis and treatments. Topics: II. Epidemiology and pathophysiology of acute kidney injury. Nihon Naika Gakkai Zasshi 103:1055–1060
2. Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Compr Physiol 2:1303–1353
3. Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121:4210–4221
4. Hewitt SM, Dear J, Star RA (2004) Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 15:1677–1689
5. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237–244
6. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238
7. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL (2002) Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110:1083–1091
8. Murray PT, Mehta RL, Shaw A, Ronco C, Endre Z, Kellum JA, Chawla LS, Cruz D, Ince C, Okusa MD (2014) Potential markers of biomarkers in acute kidney injury: report and summary of recommendations from the 10th acute dialysis quality initiative consensus conference. Kidney Int 85:513–521
9. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597–610
10. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666
11. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106:4402–4407
12. Ng EK, Chong WW, Jin H, Lam EK, Shin YY, Yu J, Poon TC, Ng SS, Sung JJ (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58:1375–1381
13. Trionfini P, Benigni A, Remuzzi G (2015) MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 11:23–33
14. Aguado-Fraile E, Ramos E, Conde E, Rodriguez M, Liano F, Garcia-Bermejo ML (2013) MicroRNAs in the kidney: novel biomarkers of acute kidney injury. Nefrologia 33:826–834
15. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T (2011) Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 6:1540–1546
16. Du J, Cao X, Zou L, Chen Y, Guo J, Chen Z, Hu S, Zheng Z (2013) MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS ONE 8:e63390
17. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC (2006) Delayed administration of darbepeotin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69:1806–1813
18. Kdigo AKI (2011) Work Group. Kdigo clinical practice guideline for acute kidney injury. Kidney Int 2012(Suppl 2):6
19. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ (2007) TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117:2847–2859
20. Wang JF, Zha YF, Li HW, Wang F, Bian Q, Lai XL, Yu G (2014) Screening plasma miRNAs as biomarkers for renal ischemia-reperfusion injury in rats. Med Sci Monit 20:283–289
21. Bellinger MA, Bean JS, Rader MA, Heinz-Taeheny KM, Nunes JS, Haas JV, Michael LF, Rekhter MD (2014) Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury: time course in a mouse model of bilateral renal ischemia-reperfusion. PLoS ONE 9:e93297
22. Saikumar J, Hoffmann D, Kim TM, Gonzalez VR, Zhang Q, Goering PL, Brown RP, Bijol V, Park PJ, Waikar SS, Vaidya VS (2012) Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 129:256–267
23. Xu L, Yang BF, Ai J (2013) MicroRNA transport: a new way in cell communication. J Cell Physiol 228:1713–1719
24. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Scholer A, Weber C (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2:ra81
25. Rayner KJ, Hennessy El (2013) Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 54:1174–1181
26. Cantaluppi V, Gatti S, Medica D, Figliolini F, Bruno S, Deregibus MC, Sordi A, Biancone L, Tetta C, Camussi G (2012) Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82:412–427
27. Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, Kawahara Y, Komuro I (2013) Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 113:322–326
28. Che M, Li Y, Liang X, Xie B, Xue S, Qian J, Ni Z, Axelsson J, Yan Y (2011) Prevalence of acute kidney injury following cardiac surgery and related risk factors in Chinese patients. Nephron Clin Pract 117:c305–c311
29. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleave MA, Chau BN (2008) Coordinated regulation of cell cycle transcripts by
p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 68:10105–10112

30. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL, Dobbelstein M (2008) p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68:10094–10104

31. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18:367–381

32. Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, Zhu J, Xing C, Xu H (2012) microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 3:560–566

33. Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF, Chowdhury P, Leuschner I, Hoefler G, Guertl B (2012) miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 33:1014–1021

34. Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, Gautheron J, Schneider A, Schuller F, Loosen S, Luedde M, Koch A, Tacke F, Luedde T, Trautwein C, Roderburg C (2016) Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. Clin Sci (Lond) 130:1197–1207